

# Ariel Bulua Bourla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103390/publications.pdf>

Version: 2024-02-01

40  
papers

1,415  
citations

566801

15  
h-index

433756

31  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential frequency in <sc>imaging</sc>-based</sc> outcome measurement: Bias in <sc>real</sc>-world</sc> oncology <sc>comparative</sc>-effectiveness</sc> studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 46-54.	0.9	9
2	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record<sup>e</sup>-Derived Real<sup>e</sup>-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 168-178.	2.3	14
3	Cover Image, Volume 31, Issue 1. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, .	0.9	0
4	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. <i>Advances in Therapy</i> , 2022, 39, 2831-2849.	1.3	5
5	Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC. <i>Advances in Therapy</i> , 2021, 38, 1843-1859.	1.3	24
6	Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform. <i>Digital Health</i> , 2021, 7, 205520762110599.	0.9	3
7	Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. <i>PLoS ONE</i> , 2020, 15, e0227256.	1.1	42
8	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non<sup>e</sup>-Small-Cell Lung Cancer Data Set. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-13.	1.0	69
9	Real<sup>e</sup>-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non<sup>e</sup>-small cell lung cancer. <i>Cancer</i> , 2019, 125, 4019-4032.	2.0	115
10	An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non<sup>e</sup>-Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	1.0	81
11	Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , 2019, 36, 2122-2136.	1.3	111
12	Small But Mighty: The Use of Real<sup>e</sup>-World Evidence to Inform Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 87-90.	2.3	24
13	A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 161-e70.	1.9	12
14	Harnessing the Power of Real<sup>e</sup>-World Evidence (RWE): A Checklist to Ensure Regulatory<sup>e</sup>-Grade Data Quality. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 202-205.	2.3	150
15	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. <i>Seminars in Liver Disease</i> , 2018, 38, 242-251.	1.8	95
16	A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 270-270.	0.8	0
17	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
18	Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. <i>Surgery</i> , 2017, 162, 275-284.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Cabozantinib in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2017, 13, 1915-1929.	1.1	10
20	SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3506-3506.	0.8	14
21	A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4075-4075.	0.8	3
22	Neoadjuvant therapy versus upfront surgery for pancreatic adenocarcinoma: A propensity score matched analysis of short-term outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-361.	0.8	7
23	Effect of adjuvant therapy on resected gallbladder adenocarcinoma: A propensity score matched analysis of national data.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15669-e15669.	0.8	0
24	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1622-1635.	1.1	18
25	Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. <i>Scientific Reports</i> , 2016, 6, 33121.	1.6	28
26	Does clinical stage predict pathologic stage in pancreatic adenocarcinoma?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4118-4118.	0.8	2
27	Trends in treatment and survival for advanced pancreatic cancer: Progress or progression?. <i>Journal of Clinical Oncology</i> , 2016, 34, 421-421.	0.8	1
28	Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 451-451.	0.8	0
29	The DASH Study: A phase 1b study of dalantercept plus sorafenib in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS495-TPS495.	0.8	0
30	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. <i>Journal of Hepatology</i> , 2014, 61, 840-849.	1.8	131
31	Comparison of Hispanic and non-Hispanic patients with HCC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 294-294.	0.8	1
32	Use of staging and scoring systems in hepatocellular carcinoma (HCC): Lessons from U.S. regional analysis of the GIDEON registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, 323-323.	0.8	1
33	Potential factors influencing initial sorafenib dose selection in hepatocellular carcinoma (HCC): U.S. regional analysis of GIDEON.. <i>Journal of Clinical Oncology</i> , 2014, 32, 304-304.	0.8	0
34	Totally implantable venous access device use in pancreatic cancer: A national analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15188-e15188.	0.8	0
35	Hepatocellular carcinoma and end-of-life care.. <i>Journal of Clinical Oncology</i> , 2014, 32, 278-278.	0.8	0
36	Hepatocellular cancer tumor growth and metabolic risk factors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 162-162.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Expanding patient-reported outcomes to oral health complications from systemic cancer therapy.. Journal of Clinical Oncology, 2012, 30, 60-60.	0.8	6
38	Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2245-2252.	0.8	19
39	Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer. Journal of Gastrointestinal Cancer, 2009, 40, 119-122.	0.6	3
40	Progression-free survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care, 2008, 24, 371-383.	0.2	82